BRCA2 variants and cardiovascular disease in a multi-ethnic study by Zbuk, Kevin et al.
RESEARCH ARTICLE Open Access
BRCA2 Variants and cardiovascular disease in a
multi-ethnic study
Kevin Zbuk1,6, Changchun Xie1,7, Robin Young2, Mahyar Heydarpour1, Guillaume Pare1,8, A Darlene Davis3,
Ruby Miller3, Matthew B Lanktree4, Danish Saleheen2,10,11, John Danesh2, Salim Yusuf1,7, James C Engert5,
Robert A Hegele4 and Sonia S Anand1,7,9*
Abstract
Background: Germline mutations of BRCA1/2 are associated with hereditary breast and ovarian cancer. Recent data
suggests excess mortality in mutation carriers beyond that conferred by neoplasia, and recent in vivo and in vitro
studies suggest a modulatory role for BRCA proteins in endothelial and cardiomyocyte function. We therefore
tested the association of BRCA2 variants with clinical cardiovascular disease (CVD).
Methods: Using data from 1,170 individuals included in two multi-ethnic population-based studies (SHARE and
SHARE-AP), the association between BRCA2 variants and CVD was evaluated. 15 SNPs in BRCA2 with minor allele
frequencies (MAF)> 0.01 had been previously genotyped using the cardiovascular gene-centric 50 k SNP array. 115
individuals (9.8%) reported a CVD event, defined as myocardial infarction (MI), angina, silent MI, stroke, and
angioplasty or coronary artery bypass surgery. Analyses were adjusted for age and sex. The SNPs rs11571836 and
rs1799943 were subsequently genotyped using the MassARRAY platform in 1,045 cases of incident MI and 1,135
controls from the South Asian subset of an international case-control study of acute MI (INTERHEART), and
rs11571836 was imputed in 4,686 cases and 4500 controls from the Pakistan Risk of Myocardial Infarction Study
(PROMIS).
Results: Two BRCA2 SNPs, rs11571836 and rs1799943, both located in untranslated regions, were associated with
lower risk of CVD (OR 0.47 p = 0.01 and OR 0.56 p = 0.03 respectively) in the SHARE studies. Analysis by specific
ethnicities demonstrated an association with CVD for both SNPs in Aboriginal People, and for rs11571836 only in
South Asians. No association was observed in the European and Chinese subgroups. A non-significant trend
towards an association between rs11571836 and lower risk of MI was observed in South Asians from INTERHEART
[OR = 0.87 (95% CI: 0.75-1.01) p = 0.068], but was not evident in PROMIS [OR = 0.96 (95% CI: 0.90-1.03) p = 0.230].
Meta-analysis of both case-control studies resulted in a combined OR of 0.94 (95% CI: 0.89-1.004, p = 0.06).
Conclusions: Although there was an association between two SNPs in BRCA2 and CVD in a multi-ethnic
population, these results were not replicated in two South Asian case-control studies of incident MI. Future studies
exploring the association between BRCA variants and cardiovascular disorders are needed to clarify the role, if any,
for BRCA variants in CVD pathogenesis.
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Background
Germline mutations of the genes BRCA1 (breast cancer
1, early onset) and BRCA2 (breast cancer 2, early onset)
are the most common cause of hereditary breast and
ovarian cancer. Autosomal dominant mutations in
BRCA1/2 are associated with a lifetime risk of breast
and ovarian cancer of up to 85% and 45% respectively
[1]. In addition, mutation carriers are at increased risk of
several additional cancers including male breast cancer,
pancreatic adenocarcinoma, prostate cancer, and melan-
oma [2]. A recent publication has suggested BRCA mu-
tation carriers have an excess risk of mortality compared
to non-carriers beyond that explained by the develop-
ment or treatment of malignancy [3]. Mai et al. utilized
a kin-cohort analysis to estimate the effect of BRCA1/2
mutations on mortality. When deaths related to cancer
diagnosis were excluded, the difference in life expectancy
was 5.7 years lower for women and 3.7 years for men
with mutations compared to age matched non-mutation
carriers. The etiology of this excess mortality is currently
unknown. However, BRCA1 and BRCA2 are members of
a complex network of proteins involved in DNA repair
and genomic stability [4], suggesting their role could ex-
tend beyond regulation of neoplasia.
Recently, a cardiomyocyte specific BRCA1 knockout
mouse was developed, which showed increased suscepti-
bility to myocardial ischemia and genotoxic agents
(doxorubicin), suggesting BRCA dysfunction might play
a role in cardiac damage during myocardial infarction
and genotoxin induced cardiotoxicity [5]. In a separate
study, cardiomyocyte specific BRCA2 knockout mice
exhibited similar susceptibility to genotoxic agents [6].
There was an association between increased double
stranded DNA breaks and cardiac damage in both
reports irrespective of the precipitating cause, alluding
to the possibility of similarities in pathogenesis [5,6].
The idea of overlapping functions for BRCA1 and
BRCA2 is further supported by evidence that the two
proteins co-localize in the nucleus and play crucial roles
in DNA repair [4]. In addition, the cancer phenotypes
expressed by germline mutations in both genes are simi-
lar [7].
BRCA mutations that are associated with a markedly
increased risk of cancer (most often resulting in protein
truncation) are extremely rare in the general population
[8]. There are however, several hundred single nucleo-
tide polymorphisms (SNPs) in BRCA1/2, many of which
are common [9]. We hypothesized that common poly-
morphisms in BRCA genes may be associated with car-
diovascular disease (CVD), another complex trait, with
molecular evidence (see above) suggesting a role for the
BRCA genes.
To test this hypothesis, we assessed the association be-
tween SNPs in BRCA and CVD in individuals from the
multi-ethnic SHARE and SHARE-AP studies [10,11].
These cross-sectional, randomly sampled, population-
based studies explored differences in CVD risk factors
and prevalence in South Asian, European, Chinese, and
Aboriginal ethnic groups residing in Canada. The
SHARE studies demonstrated that Aboriginal people
and South Asians had the highest prevalence of CVD
amongst the four ethnic groups [10,11].
Methods
Overall approach
We analyzed SHARE and SHARE-AP data that was
available from the prior genotyping of 50,000 SNPs from
candidate genes and pathways for cardiovascular, inflam-
matory and metabolic phenotypes in these study popula-
tions [12-14]. The Illumina HumanCVD beadchip array
includes twenty-one SNPs in BRCA2 with MAF >0.01
but does not include any SNPs in BRCA1.
Due to the availability of DNA samples from South
Asians, we examined the association between
rs11571836 and rs1799943 and incident MI in South
Asians from the INTERHEART. INTERHEART is a
large, global, standardized case-control study of incident
MI from 52 countries [15]. We next became aware of
genome wide genotyping data from the PROMIS study,
a similar case-control study of incident MI amongst
South Asians residing in urban regions of Pakistan [16].
Since our analysis of INTERHEART showed a trend to-
wards an association between MI and rs11571836, but
no association between MI and rs1799943, we examined
the association of rs11571836 and MI using imputation
in the PROMIS analysis.
Informed consent and REB approval
All studies were approved by appropriate research ethics
boards. In addition, all participants provided informed
consent, including consent for the collection and proces-
sing of genetic material in accordance with TriCouncil
guidelines.
SHARE studies
The methodology and results of the SHARE studies are
described in detail elsewhere [10,11]. At the time of en-
rolment, no participant had a diagnosis of cancer. Cana-
dians were classified as South Asian if their ancestors
originated from India, Pakistan, Sri Lanka, or Bangla-
desh; Chinese if their ancestors originated from China,
Taiwan, or Hong Kong; and European if their ancestors
originated from Europe. Aboriginal people were identi-
fied as such if they were members of the Six Nations
Band. CVD was defined as prevalent cases of myocardial
infarction, angina, coronary angioplasty or CABG, silent
myocardial infarction defined by major Q waves on ECG,
and stroke as previously described. The ascertainment of
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CVD events was from self-administered questionnaires,
medical records, and electrocardiograms [17].
Genotyping of the SHARE and SHARE-AP samples on
the Illumina HumanCVD beadchip had been previously
carried out, utilizing standard protocols at two locations,
as described in detail elsewhere [13,14]. The three ethnic
groups in SHARE were genotyped at The Centre for Ap-
plied Genomics (Hospital for Sick Children, Toronto,
Ontario; www.tcag.ca), and the Aboriginal people from
SHARE-AP were genotyped at the McGill University
and Genome Quebec Innovation Centre (Montreal,
Quebec;www.genomequebec.com).
Replication studies (INTERHEART and PROMIS)
The methodology and results of the INTERHEART and
PROMIS studies are described in detail elsewhere
[15,16]. For both studies, individuals presenting to hos-
pitals with acute MI defined cases, while controls were
generally patients from the same hospital with no history
of cardiovascular disease. The identification of South
Asian ethnicity in INTERHEART was based on self-
reported ethnicity. However, individuals with self-
reported ethnicity that differed from genetically inferred
ancestry were excluded from the analysis as previously
described [18]. Genotyping of rs11571836 in 1,143 cases
and 1,218 controls of South Asian ethnicity from
INTERHEART was performed at the McGill University
and Genome Quebec Innovation Centre (Montreal,
Quebec;www.genomequebec.com) using the MassAR-
RAY platform as previously described [19].
Participants of PROMIS were recruited from hospitals
of four large urban centres in Pakistan. South Asians
were defined as those with ancestry from the Indian sub-
continent. As part of PROMIS, 4,686 cases of incident
MI and 4,500 controls had been previously genotyped at
the Center for Non-Communicable Diseases (Karachi,
Pakistan) using the Illumina 660 genome wide associ-
ation platform as described elsewhere [20]. This array
has SNPs spaced at an average of approximately 4 kb
intervals. The genotype of rs11571836 was imputed in
cases and controls using the software IMPUTE [21]. The
Hapmap Phase 2 population (270 individuals) combined
with the South Asian samples from Phase 3 (90 indivi-
duals) served as the reference samples for the imput-
ation (hapmap.ncbi.nlm.nih.gov).
Statistical analysis
Analyses were performed using SAS (version 8.2; SAS
Institute, Cary, NC) and PLINK [22]. Linkage disequilib-
rium (LD) maps and r2 values were produced using Hap-
loview 4.0 [23]. In SHARE and SHARE-AP BRCA2
SNPs were tested for their association with prevalent
CVD, in each ethnicity, using logistic regression analysis
assuming an additive model. Analyses were adjusted for
age and sex. The association results for each ethnicity
were thereaftercombined utilizing a fixed-effect meta-
analysis, adjusted for multiple comparison. The associ-
ation between incident MI and rs11571836 and
rs1799943 was tested in South Asians from the INTER-
HEART study using logistic regression with an additive
model, adjusted for age and sex. Association testing of
imputed genotypes with MI in the PROMIS study was
performed using SNPTEST [23,24] utilizing a logistic re-
gression model adjusted for age and sex. A fixed effects
meta-analysis combining the association results for
rs11571836 and CVD (for the SHARE studies) or MI
(for INTERHEART AND PROMIS) from all three stud-
ies was performed using PLINK.
Quality control
Of the 21 BRCA2 SNPs present on the HumanCVD
beadchip with MAF greater than 0.01 six were excluded
as call rates were less than 95% in one or more ethnici-
ties. For the remaining 15 SNPs call rates were in excess
of 97% in all ethnicities. In addition, 15 individuals were
excluded because of genotype call rates less than 95%
for the 15 SNPs. There was no significant deviation from
Hardy Weinberg equilibrium as tested within each eth-
nic group (all p values >0.1). Genotyping of rs11571836
in the INTERHEART samples resulted in a call rate of
98%. The quality of imputation of rs11571836 from
PROMIS, as measured by the SNPtest info score was
0.978. No samples were excluded due to poor imput-
ation confidence.
Results
SHARE and SHARE-AP
Of 1,178 individuals with complete genotyping, 115 indi-
viduals had at least one CVD outcome (9.8%). Tables 1
and 2 show CVD associations by ethnicity for
rs11571836 and rs1799943. CVD was more prevalent in
the Aboriginal and South Asian groups compared with
the European and Chinese groups. In the case of
rs11571836 (Table 1) the association was statistically sig-
nificant for the Aboriginal and South Asian sub-groups
while for rs1799943 (Table 2) the association was statis-
tically significant only in the Aboriginal group. Both
SNPs were associated with CVD in meta-analyses that
the combined association results for all four ethnicities.
For rs11571836 the combined OR was 0.56 (p value
0.009) while for rs1799943 the combined OR was 0.60
(p value 0.01). The I2 test for heterogeneity was 0% for
both meta-analyses. There was no association between
CVD and any of the other BRCA2 SNPs examined (Add-
itional file 1: Table S1).
Figure 1 shows the LD patterns by ethnicity for SNPs
in BRCA2 genotyped in this study. There are significant
differences in LD distribution, as defined by LD blocks,
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between the four ethnic groups. Additionally, there is
more LD in this region in the Chinese, South Asian and
Aboriginal groups compared to the European group.
However, there was no significant LD between
rs1799943 and rs11571836 (r2 <0.2) in any ethnicity.
The SNP rs11571836 is located in the 3’ UTR of BRCA2,
while rs1799943 is in the 5’UTR.
Replication studies (INTERHEART AND PROMIS)
Figure 2 illustrates the results of association analyses be-
tween rs11571836 and incident MI in the South Asian
INTERHEART and PROMIS studies, including meta-
analysis combining the two studies. There was a trend
towards an association between rs11571836 and MI in
the INTERHEART analysis [OR= 0.87 (95% CI: 0.75-
1.01], which did not reach statistical significance
(p = 0.068). In contrast, there was no association between
MI and rs1799943, p = 0.3 [OR-0.93 (95% CI 0.821-
1.062)]. There was no significant association between
rs11571836 and incident MI in the PROMIS association
study [OR= 0.96 (95% CI: 0.90-1.03) p = 0.23].
Finally, meta-analysis of the replication studies (PRO-
MIS and INTERHEART) for rs111571836 resulted in a
combined OR of 0.94 (95% CI: 0.89-1.004, p = 0.066).
The I2 test for heterogeneity was 28% (low to moderate).
We also performed a meta-analysis utilizing the CVD
association results for the South Asian subgroup of
SHARE, combined with the association results for acute
MI from the two replication studies. Although the re-
sulting odds ratio (OR= 0.9) and p-value (p = 0.05) were
marginally lower, the level of heterogeneity was much
higher (I2 = 68%, Chi-squared heterogeneity statistic >3
with 2 degrees of freedom). We therefore did not in-
clude the SHARE results in the final meta-analysis and
resulting forest plot (Figure 2).
Discussion
To our knowledge, this report is the first to suggest a
possible association between variants in BRCA1/2 and
CVD in human populations. However this observation
requires confirmation, given that the effect size appears
to be small, and our meta-analysis did not reach statis-
tical significance. It is possible that the association we
observed in the SHARE studies was due to chance alone,
and is not a true association.
Very little has been published with respect to shared
genetic predisposition to cancer and CVD. However,
mechanistically, several common pathways are emerging.
Most prominent in recent publications is the endothelin
axis, with reports linking endothelin-1 to prostate cancer
tumorigenesis [25]. Additionally, animal models demon-
strate upregulation of DNA repair mechanisms in heart
failure induced by ischemic damage [26]. As an example,
topoisomerase-II-alpha, a protein involved in various
aspects of DNA repair, is overexpressed in unstable
plaque from human carotid atheromas [27]. Given its in-
tegral role in genomic stability and DNA repair, a similar
role in the pathogenesis of coronary atherosclerosis,
plaque rupture, and response to ischemic damage may
exist for BRCA1/2. Finally, several SNPs associated with
metabolic diseases, identified through genome wide as-
sociation studies, have roles in cancer and chronic
Table 2 Association test results for rs1799943 and CVD (SHARE+AP)
Ethnicity Individuals with at least one
CVD event (% of total)
Individuals with no
CVD events (n)
MAF (A allele) * OR (95% CI) P
All combined+ 115 (10%) 1063 range: 0.18-0.37 0.6 0.01
Aboriginal 55 (19%) 235 0.18 0.40 (0.19-0.83) 0.007
South Asian 32 (10%) 291 0.32 0.58 (0.29-1.13) 0.10
European 20 (8%) 245 0.25 0.79 (0.35-1.78) 0.55
Chinese 8 (3%) 292 0.37 1.00 (0.35-2.86) 0.99
+ meta-analysis (fixed-effect model) adjusted for multiple comparisons.
*MAF calculated from cases and controls combined for each ethnicity.
Table 1 Association test results for rs11571836 and CVD (SHARE+AP)
Ethnicity Individuals with at least one
CVD event (% of total)
Individuals with no
CVD events (n)
MAF (G allele)* OR (95% CI) P
All combined+ 115 (10%) 1063 range: 0.15-.038 0.56 0.009
Aboriginal 55 (19%) 235 0.15 0.42 (0.19-0.91) 0.017
South Asian 32 (10%) 291 0.23 0.43 (0.19-0.99) 0.021
European 20 (8%) 245 0.20 0.37 (0.08-1.63) 0.19
Chinese 8 (3%) 292 0.38 0.99 (0.35-2.9) 0.99
+ meta-analysis (fixed-effect model) adjusted for multiple comparisons.
*MAF calculated from cases and controls combined for each ethnicity.
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disease predisposition. For example, variants in TCF7L2
predispose to both colon cancer and type 2 diabetes
while variants in HNF1B predisposes to type 2 diabetes
and prostate cancer [28].
Our study suggested a possible association between
rs11571836 and rs1799943 and CVD in a multi-ethnic
population. Analysis by ethnicity confirmed a statistically
significant association with Aboriginal and South Asian
ethnicities for rs11571836, while for rs1799943 the asso-
ciation was statistically significant only in the Aboriginal
group. It is worth noting however, that with the excep-
tion of the Chinese group, all odds ratios trended in the
same direction (ie. below 1) for both SNPs. This sup-
ports the possible explanation that the current analysis
was underpowered to detect an association by individual
ethnicity. In fact, only 17% and 6.9% of individuals with
CVD in the study were European or Chinese respect-
ively. Alternatively, lack of association between these
SNPs and CVD in specific ethnicities may represent dif-
ferences in LD in the region encompassing BRCA2, as
there are significant differences in LD structure in this
region among ethnicities (Figure 1). In silico analysis of
these two SNPs suggests both may modulate BRCA2
transcript levels [29], but there have been no published
Figure 1 Linkage disequilibrium maps ofBRCAregion for the 4 ethnic groups. A) Aboriginal B) Chinese C) European D) South Asian.
Arrowheads in panel A indicate position of rs11571836 (right arrow) and rs1799943 (left arrow).
Figure 2 Meta-analysis of the association between rs11571836
and MI from INTERHEART and PROMIS (fixed effects model).
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functional studies to date. Similarly, neither SNP has
been definitively associated with breast cancer suscepti-
bility. Thus, it is quite possible that rs11571836 and
rs1799943 are not directly associated with CVD, but in-
stead are in LD with other functional variants associated
with CVD. Finally, there may be ethnic-specific differ-
ences in the pathogenesis of CVD such that BRCA vari-
ation is only relevant to CVD in certain ethnicities,
although this seems unlikely given the consistency of
other risk factors for CVD across ethnicities [15].
We were unable to demonstrate a statistically signifi-
cant association between rs11571836 and incident MI in
two large case controls studies of incident MI in South
Asians, although a trend towards an association was
present in INTERHEART. It is possible in INTER-
HEART that a larger sample size may have resulted in a
statistically significant association, as the current sample
size was underpowered (44% power) to detect a 15% risk
reduction in MI risk for allele frequencies of 20%. A
sample size of approximately 2600 cases and a similar
number of controls is required to reach 80% power.
Based on sample size, the PROMIS analysis was ad-
equately powered, however, it is possible that utilizing
imputation to infer the genotype of rs11571836 may
have resulted in divergent results from what would have
been observed had the SNP been directly genotyped.
While the literature suggests good concordance between
imputation and direct genotyping [30], it is possible that
the HapMap reference samples were not adequate for
this region. Alternatively, subtle differences in LD pat-
terns between South Asian populations could explain the
lack of a reproducible association between rs11571836
and acute MI in the SHARE, INTERHEART and PRO-
MIS studies. Conversely, the lack of replication would be
anticipated if the association between BRCA2 variants
and CVD demonstrated in the SHARE studies occurred
by chance. One means of further clarifying this possibility
is to examine the association between BRCA2 variants
and CAD in published GWAS studies. There was no as-
sociation between either rs11571836 or rs1799943 and
CAD in the Wellcome Trust Case Control Consortium
(WTCCC) GWAS study [31]. However, the WTCCC
study was composed exclusively of White Europeans, un-
like our multi-ethnic or South Asian study populations.
Unfortunately, lack of publically available data from add-
itional multi-ethnic or South Asian GWAS studies lim-
ited our ability to “look-up” these SNPs directly in
additional studies.
Alternatively, variants in BRCA2 may be more rele-
vant to the pathogenesis of other components of the
composite CVD outcome utilized in SHARE (for exam-
ple ischemic stroke), rather than acute MI. One signif-
icant limitation of utilizing the composite CVD outcome
in genetic association studies is the heterogeneous
pathogenesis of the outcomes studied. In the SHARE
studies, the low number of events precluded an assess-
ment of individual components of the composite CVD
outcome. Testing the association between BRCA variants
and measures of CVD other than MI, ideally from mul-
tiple ethnicities, could confirm or refute this hypothesis.
In addition, experimental data has thus far only demon-
strated a role for BRCA1 in the modulation of cardio-
myocyte function following ischemic damage. Due to
resource constraints, our analysis was limited to SNPs
from BRCA2 that had been previously genotyped, how-
ever, investigating the role of SNPs in BRCA1 would
be desirable. Finally, data from the murine knock-out
models described earlier allude to the possibility that
BRCA1/2 may play a greater role in modulating the
severity of cardiomyocyte damage following an insult,
rather than being directly implicated in initiation of car-
diac injury. Therefore, testing the association between
variants in the BRCA genes and the severity of a CVD
outcome might prove more useful.
Conclusions
Our results suggested a possible association between
BRCA2 and CVD in the multi-ethnic SHARE study,
however we were unable to replicate this association in
two large case-control studies of acute MI in South
Asians. Future studies exploring the association between
BRCA1/2 variants and CVD outcomes, may help clarify
the role, if any, of BRCA variants in CVD pathogenesis.
Additional file
Additional file 1: Table S1. Association Test Results for BRCA2 SNPs
and CVD (SHARE+AP).
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